Literature DB >> 20007380

Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States.

Naureen Iqbal1, Emilio E DeBess, Ron Wohrle, Ben Sun, Randall J Nett, Angela M Ahlquist, Tom Chiller, Shawn R Lockhart.   

Abstract

Cryptococcus gattii emerged in North America in 1999 as a human and veterinary pathogen on Vancouver Island, British Columbia. The emergent subtype, VGIIa, and the closely related subtype VGIIb can now be found in the United States in Washington, Oregon, and California. We performed multilocus sequence typing and antifungal susceptibility testing on 43 isolates of C. gattii from human patients in Oregon, Washington, California, and Idaho. In contrast to Vancouver Island, VGIIa was the most frequent but not the predominant subtype in the northwest United States. Antifungal susceptibility testing showed statistically significant differences in MICs between the subtypes. This is the first study to apply antifungal susceptibility testing to C. gattii isolates from the Pacific Northwest and the first to make direct comparisons between subtypes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007380      PMCID: PMC2815610          DOI: 10.1128/JCM.01505-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole.

Authors:  Yolanda Morera-López; Josep M Torres-Rodríguez; Teresa Jiménez-Cabello; Teresa Baró-Tomás
Journal:  Med Mycol       Date:  2005-09       Impact factor: 4.076

2.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Molecular epidemiology of clinical Cryptococcus neoformans strains from India.

Authors:  N Jain; B L Wickes; S M Keller; J Fu; A Casadevall; P Jain; M A Ragan; U Banerjee; B C Fries
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

4.  Cryptococcus gattii in wildlife of Vancouver Island, British Columbia, Canada.

Authors:  C Duncan; H Schwantje; C Stephen; J Campbell; K Bartlett
Journal:  J Wildl Dis       Date:  2006-01       Impact factor: 1.535

5.  Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak.

Authors:  James A Fraser; Steven S Giles; Emily C Wenink; Scarlett G Geunes-Boyer; Jo Rae Wright; Stephanie Diezmann; Andria Allen; Jason E Stajich; Fred S Dietrich; John R Perfect; Joseph Heitman
Journal:  Nature       Date:  2005-10-09       Impact factor: 49.962

6.  A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada).

Authors:  S E Kidd; F Hagen; R L Tscharke; M Huynh; K H Bartlett; M Fyfe; L Macdougall; T Boekhout; K J Kwon-Chung; W Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-30       Impact factor: 11.205

7.  Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group.

Authors:  M E Brandt; L C Hutwagner; L A Klug; W S Baughman; D Rimland; E A Graviss; R J Hamill; C Thomas; P G Pappas; A L Reingold; R W Pinner
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

8.  Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology.

Authors:  Linda M N Hoang; John A Maguire; Patrick Doyle; Murray Fyfe; Diane L Roscoe
Journal:  J Med Microbiol       Date:  2004-09       Impact factor: 2.472

9.  First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreak.

Authors:  Arlo Upton; James A Fraser; Sarah E Kidd; Camille Bretz; Karen H Bartlett; Joseph Heitman; Kieren A Marr
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

10.  In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii.

Authors:  C De Bedout; N Ordóñez; B L Gómez; M C Rodríguez; M Arango; A Restrepo; E Castañeda
Journal:  Rev Iberoam Micol       Date:  1999-03       Impact factor: 1.044

View more
  42 in total

1.  Cryptococcus gattii as an important fungal pathogen of western North America.

Authors:  Kieren A Marr
Journal:  Expert Rev Anti Infect Ther       Date:  2012-06       Impact factor: 5.091

2.  Macrolides Inhibit Capsule Formation of Highly Virulent Cryptococcus gattii and Promote Innate Immune Susceptibility.

Authors:  Shigeki Nakamura; Yurika Ikeda-Dantsuji; Lianjin Jin; Yoshitsugu Higashi; Masahiro Abe; Tatsuya Inukai; Minoru Nagi; Makoto Urai; Yoshitsugu Miyazaki
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Identification and properties of plasma membrane azole efflux pumps from the pathogenic fungi Cryptococcus gattii and Cryptococcus neoformans.

Authors:  Luiz R Basso; Charles E Gast; Igor Bruzual; Brian Wong
Journal:  J Antimicrob Chemother       Date:  2015-01-27       Impact factor: 5.790

4.  Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility.

Authors:  K Datta; P Rhee; E Byrnes; G Garcia-Effron; D S Perlin; J F Staab; K A Marr
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

5.  Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.

Authors:  P F Herkert; F Hagen; G L de Oliveira Salvador; R R Gomes; M S Ferreira; V A Vicente; M D Muro; R L Pinheiro; J F Meis; F Queiroz-Telles
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-01       Impact factor: 3.267

6.  Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.

Authors:  A Espinel-Ingroff; A Chowdhary; M Cuenca-Estrella; A Fothergill; J Fuller; F Hagen; N Govender; J Guarro; E Johnson; C Lass-Flörl; S R Lockhart; M A Martins; J F Meis; M S C Melhem; L Ostrosky-Zeichner; T Pelaez; M A Pfaller; W A Schell; L Trilles; S Kidd; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

7.  Molecular typing of clinical isolates of Cryptococcus neoformans/Cryptococcus gattii species complex from Northeast Mexico.

Authors:  Gloria M González; Néstor Casillas-Vega; Elvira Garza-González; Romel Hernández-Bello; Gildardo Rivera; Jesús Ancer Rodríguez; Virgilio Bocanegra-Garcia
Journal:  Folia Microbiol (Praha)       Date:  2015-06-25       Impact factor: 2.099

8.  Rapid identification of Cryptococcus neoformans and Cryptococcus gattii by matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Lisa R McTaggart; Eric Lei; Susan E Richardson; Linda Hoang; Annette Fothergill; Sean X Zhang
Journal:  J Clin Microbiol       Date:  2011-06-08       Impact factor: 5.948

9.  The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.

Authors:  Shawn R Lockhart; Annette W Fothergill; Naureen Iqbal; Carol B Bolden; Nina T Grossman; Edward P Garvey; Stephen R Brand; William J Hoekstra; Robert J Schotzinger; Elizabeth Ottinger; Thomas F Patterson; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

10.  Detection of Cryptococcus gattii in selected urban parks of the Willamette Valley, Oregon.

Authors:  Jack A Mortenson; Karen H Bartlett; Randy W Wilson; Shawn R Lockhart
Journal:  Mycopathologia       Date:  2013-01-26       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.